Myocant Sciences complets screening patients for heavy menstrual bleeding study

Myovant Sciences has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating relugolix in women with heavy menstrual bleeding associated with uterine fibroids.

Uterine fibroids are debilitating and result in heavy menstrual bleeding in millions of women throughout the world, often requiring a hysterectomy. Myovant is working to develop relugolix, an oral, once-daily medication, to potentially provide women with an alternative to invasive procedures and major surgery for the treatment of uterine fibroids.

“Completion of screening for LIBERTY 1 is a critical milestone for our uterine fibroids program,” said Lynn Seely, M.D., President and CEO of Myovant. “We look forward to completing screening for LIBERTY 2 this quarter and reporting top-line efficacy and safety data for LIBERTY 1 in the second quarter of 2019. Today’s announcement is the first of several milestones we expect to report as we continue to diligently work toward top-line results on all of our ongoing Phase 3 clinical studies during 2019.”